Novavax Vaccine getting ready to apply for full approval
CHATTANOOGA, Tenn (WDEF) – The Novavax Covid vaccine has undergone months of clinical trials against not only the original coronavirus strain but also the new variants.
The Maryland based biotech company says its 2 dose vaccine is around 90 percent effective and is safe – after being tested on nearly 30 thousand trial participants.
“Where we are currently as investigators reviewing data with the sponsor. The FDA is looking at safety data and following up with patients who were vaccinated early this year to see if any of them have breakthrough cases and then trying to give efficacy results to the public so we can have another option out there for Covid,” says Dr. Mark McKenzie, Regional Medical Director for ClinSearch.
Recently The CDC announced that participants in the Novavax PREVENT-19 Phase 3 clinical trial are considered fully vaccinated two weeks after they have completed the vaccine series.
Chattanooga resident Brooke Marsh was one of these participants.
“I was really glad to hear that they considered it fully vaccinated. It’s a more traditional vaccine. I have had nothing but good experiences from it. I didn’t have any side effects from either set of shots. I think they are very trustworthy,” says Marsh.
The company says they plan to seek full authorization to distribute the vaccine within the next few months- with the focus being on low to middle income countries.
“It’s a different type of vaccine though. Moderna and Pfizer are mRNA vaccines. This one is a protein subunit vaccine. It’s a type of vaccine that we have used for flu, hepatitis, and HPV in the past. But this one is targeting the world. It will be available to people around the world in addition to what’s out there. Hopefully it will be at a lower cost for some countries that don’t have the resources like the United States has,” says Dr. McKenzie.
Dr. Mark McKenzie is hoping that with this fourth vaccine being a more familiar type of vaccine – those who have felt uneasy, will finally feel comfortable with getting vaccinated.
On Tuesday, Japan secured 150 million doses of the Novavax vaccine.